JPH0427840B2 - - Google Patents
Info
- Publication number
- JPH0427840B2 JPH0427840B2 JP58501036A JP50103683A JPH0427840B2 JP H0427840 B2 JPH0427840 B2 JP H0427840B2 JP 58501036 A JP58501036 A JP 58501036A JP 50103683 A JP50103683 A JP 50103683A JP H0427840 B2 JPH0427840 B2 JP H0427840B2
- Authority
- JP
- Japan
- Prior art keywords
- dna
- hla
- probe
- fragments
- alleles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108020004414 DNA Proteins 0.000 description 128
- 102000053602 DNA Human genes 0.000 description 128
- 239000000523 sample Substances 0.000 description 116
- 239000012634 fragment Substances 0.000 description 109
- 108700028369 Alleles Proteins 0.000 description 76
- 108091007433 antigens Proteins 0.000 description 63
- 239000000427 antigen Substances 0.000 description 62
- 102000036639 antigens Human genes 0.000 description 62
- 238000000034 method Methods 0.000 description 53
- 108091008146 restriction endonucleases Proteins 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 34
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 30
- 239000002299 complementary DNA Substances 0.000 description 30
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 25
- 238000009396 hybridization Methods 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 238000009826 distribution Methods 0.000 description 15
- 238000003776 cleavage reaction Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000007017 scission Effects 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 108010048896 HLA-D Antigens Proteins 0.000 description 10
- 108010058597 HLA-DR Antigens Proteins 0.000 description 10
- 102000006354 HLA-DR Antigens Human genes 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 230000000405 serological effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 102000009485 HLA-D Antigens Human genes 0.000 description 9
- 108010064885 HLA-DR3 Antigen Proteins 0.000 description 8
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 102000011786 HLA-A Antigens Human genes 0.000 description 5
- 108010075704 HLA-A Antigens Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010051539 HLA-DR2 Antigen Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- -1 cofactors Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000009402 cross-breeding Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241001479434 Agfa Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 101000588987 Caenorhabditis elegans Myosin-1 Proteins 0.000 description 1
- 108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 101710204040 Myosin-3 Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000736892 Thujopsis dolabrata Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK105582A DK105582A (da) | 1982-03-11 | 1982-03-11 | Fremgangsmaade til bestemmelse af humane hla-d(r) vaevstyper og gensonde til brug ved fremgangsmaaden |
| DK1055/82 | 1982-03-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59500352A JPS59500352A (ja) | 1984-03-08 |
| JPH0427840B2 true JPH0427840B2 (cg-RX-API-DMAC7.html) | 1992-05-12 |
Family
ID=8100475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58501036A Granted JPS59500352A (ja) | 1982-03-11 | 1983-03-11 | Ｍｈｃ遺伝子によりコ−ドされる組織タイプの決定方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0103000B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPS59500352A (cg-RX-API-DMAC7.html) |
| DE (1) | DE3375160D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK105582A (cg-RX-API-DMAC7.html) |
| WO (1) | WO1983003260A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582788A (en) * | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| DE3382137D1 (de) * | 1982-07-30 | 1991-02-28 | Bernard Francois Mach | Dns-sequenzenkodieren fuer den dr-beta-kettenlocus des menschlichen lymphocytantigenkomplexes und polypeptiden, diagnostische typierungsverfahren und produkte die darauf bezug haben. |
| US6818393B1 (en) | 1982-07-30 | 2004-11-16 | Biomirieux Sa | DNA sequences coding for the DR beta-chain locus of the human lymphocyte antigen complex and polypeptides, diagnostic typing processes and products related thereto |
| US4948882A (en) * | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| IL71064A (en) * | 1983-02-28 | 1989-10-31 | Lifecodes Corp | Paternity and forensic test involving analysis of dna polymorphic genetic regions |
| US5593832A (en) * | 1983-02-28 | 1997-01-14 | Lifecodes Corporation | Method for forensic analysis |
| US5821058A (en) * | 1984-01-16 | 1998-10-13 | California Institute Of Technology | Automated DNA sequencing technique |
| USRE43096E1 (en) | 1984-01-16 | 2012-01-10 | California Institute Of Technology | Tagged extendable primers and extension products |
| GB2155176B (en) * | 1984-01-16 | 1988-05-11 | California Inst Of Techn | Sequencing dna |
| WO1985004720A1 (en) * | 1984-04-05 | 1985-10-24 | Howard Florey Institute Of Experimental Physiology | Hybridization histochemistry |
| EP0342717A3 (en) * | 1984-11-12 | 1990-04-25 | THE LISTER INSTITUTE OF PREVENTIVE MEDICINE Royal National Orthopaedic Hospital | Polynucleotide probes |
| IS1355B6 (is) * | 1984-11-12 | 1989-04-19 | Lister Institute Of Preventive Medicine | Fjölkjarna kannar |
| JP2614853B2 (ja) * | 1985-06-14 | 1997-05-28 | ジェネティック システムズ コーポレイション | 増加した危機の糖尿病に関連する対立遺伝子を同定するための方法 |
| JPS62111699A (ja) * | 1985-08-05 | 1987-05-22 | コラボラテイブ・リサ−チ・インコ−ポレ−テツド | 制限断片長多形性による遺伝子型の決定 |
| EP0226288A3 (en) * | 1985-10-09 | 1989-06-28 | Collaborative Research Inc. | Means and method of testing for cystic fibrosis based on genetic linkage |
| GB8606719D0 (en) * | 1986-03-19 | 1986-04-23 | Lister Preventive Med | Genetic probes |
| US4965189A (en) * | 1986-07-01 | 1990-10-23 | University Of Massachusetts Medical School | Probes for the determination of the proclivity for development of autoimmune diseases |
| DK495186D0 (da) * | 1986-10-16 | 1986-10-16 | Nordisk Gentofte | Fremgangsmaade og middel til paavisning af genstrukturer hos personer med stor tilbaejelighed til udvikling af iddm |
| AU633958B2 (en) * | 1989-07-25 | 1993-02-11 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB9002625D0 (en) * | 1990-02-06 | 1990-04-04 | Univ Singapore | Human leukocyte antigen typing |
| US5096557A (en) * | 1990-07-11 | 1992-03-17 | Genetype A.G. | Internal standard for electrophoretic separations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394443A (en) * | 1980-12-18 | 1983-07-19 | Yale University | Method for cloning genes |
| EP0062286A1 (en) * | 1981-03-31 | 1982-10-13 | Albert Einstein College Of Medicine Of Yeshiva University | Diagnostic test for hepatitis B virus |
| CA1219824A (en) * | 1981-04-17 | 1987-03-31 | David C. Ward | Modified nucleotides and methods of preparing and using same |
| ATE53862T1 (de) * | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
-
1982
- 1982-03-11 DK DK105582A patent/DK105582A/da not_active Application Discontinuation
-
1983
- 1983-03-11 DE DE8383900983T patent/DE3375160D1/de not_active Expired
- 1983-03-11 JP JP58501036A patent/JPS59500352A/ja active Granted
- 1983-03-11 EP EP83900983A patent/EP0103000B1/en not_active Expired
- 1983-03-11 WO PCT/SE1983/000084 patent/WO1983003260A1/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| AM.J.HUM GENET=1980 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59500352A (ja) | 1984-03-08 |
| DK105582A (da) | 1983-09-12 |
| EP0103000A1 (en) | 1984-03-21 |
| DE3375160D1 (en) | 1988-02-11 |
| EP0103000B1 (en) | 1988-01-07 |
| WO1983003260A1 (en) | 1983-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0427840B2 (cg-RX-API-DMAC7.html) | ||
| Gubin et al. | Identification of the Dombrock blood group glycoprotein as a polymorphic member of the ADP-ribosyltransferase gene family | |
| US9738931B2 (en) | Non-invasive detection of fetal genetic traits | |
| Bronson et al. | Isolation and characterization of yeast artificial chromosome clones linking the HLA-B and HLA-C loci. | |
| Hill | Genetic susceptibility to malaria and other infectious diseases: from the MHC to the whole genome | |
| Lewin | Genetic organization, polymorphism, and function of the bovine major histocompatibility complex | |
| JP4201057B2 (ja) | ヒト転移サプレッサー遺伝子ｋａｉｉに由来する試薬を使用する診断方法及び遺伝子療法 | |
| EP0820469B1 (en) | Identification, purification and uses of leczymes and carbohydrate ligands | |
| US4835098A (en) | Characterization of HLA alleles with locus-specific DNA probes | |
| JP3195859B2 (ja) | ひとリンパ球抗原複合体のＤＲ−β−鎖部位の免疫学的もしくは生物学的活性を示すポリペプチドおよびその製造方法並びに診断判定方法および判定用生産物 | |
| Irshaid et al. | Genomic typing of the Kidd blood group locus by a single‐tube allele‐specific primer PCR technique | |
| GOODEVE | Laboratory methods for the genetic diagnosis of bleeding disorders | |
| Wang et al. | Apolipoprotein B: the Ag (a1/d) immunogenetic polymorphism coincides with a T-to-C substitution at nucleotide 1981, creating an Alu I restriction site. | |
| JP2000500010A (ja) | Ｒｈ血液型群の遺伝子型の診断方法及びその決定のためのキット | |
| JPH05211897A (ja) | ヌクレオチド配列 | |
| Paquay et al. | A high‐throughput Taqman® approach for the discrimination of HLA‐E alleles | |
| Lawrance et al. | Molecular approaches to the characterization of megabase regions of DNA: applications to the human major histocompatibility complex | |
| JP2000511430A (ja) | Ｈｌａ ｄｑｂ１タイピングを決定するためのヌクレオチドプローブおよび方法 | |
| CN1763196B (zh) | 基因突变类型及基因测序方法 | |
| Tanaka et al. | Gene responsible for dificient activity of the β subunit of C8, the eighth component of complement, is located on mouse chromosome 4 | |
| Seale et al. | Prenatal diagnosis of thalassemias and hemoglobinopathies | |
| Shoulders et al. | [42] Genetic polymorphism in the ApoA-I/C-III complex | |
| Brook et al. | Myotonic dystrophy and gene mapping on human chromosome 19 | |
| Dausset et al. | Molecular genetics of the HLA system: New tools for the study of HLA and disease | |
| Ryan | A search for [alpha] and [gamma] globin gene anomalies among SS and SC patient |